Shilpa Medicare Stock Up Today, After Bengaluru Facility Clears US FDA Inspection

Mumbai, July 16: Shilpa Medicare Ltd (NSE: SHILPAMED) stock price is up today after its Bengaluru-based Unit VI received “Voluntary Action Indicated” report in its US FDA inspection. Voluntary Action Indicated means that no severe objections were raised by USFDA in its inspection report.

At 12:50 p.m. 16th July,  the stock is up by 4.99% at Rs 937.

Key Market Data (as of 11:15 AM IST)

USFDA EIR Classification Details

Shilpa Medicare’s Unit VI, located in Dabaspet, Bengaluru, is a crucial facility for the company, designed for the manufacturing, packaging, testing, storage, and distribution of complex dosage forms, including Oral Dissolving Films (ODFs) and Transdermal Systems.

• Inspection Period: The GMP inspection by the USFDA was conducted from October 24 to 30, 2024.
• EIR Classification: The facility received a “Voluntary Action Indicated” (VAI) classification. This classification implies that although the investigators found and documented some objectionable conditions, the USFDA will not take or recommend regulatory or enforcement action at this time. The company is expected to address these observations voluntarily.
• Current Status: The unit already holds approvals from several international regulatory bodies, including the European Medicines Agency (EMA), the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the Saudi Food and Drug Authority (SFDA), and Australia’s Therapeutic Goods Administration (TGA).
• Product Status: The facility currently supplies ODFs to the US and other international markets. Transdermal products manufactured at this unit have been filed in the European market, indicating potential future growth.

Order Book Snapshot

Buy Quantity: 8,596

Sell Quantity: 8,525

Financial Snapshot

For the fiscal year ended March 31, 2025, Shilpa Medicare reported a significant financial improvement. The company’s consolidated net profit surged by 145.65% to ₹78.29 crore, compared to ₹31.87 crore in the previous year. Sales also saw a healthy rise of 11.71% to ₹1,286.41 crore for the full year. Furthermore, the company’s total income for Q4 FY25 was ₹294.19 crore, and it recorded a profit after tax of ₹14.51 crore for the same quarter. Shilpa Medicare’s consolidated EBITDA also improved by 30% year-on-year in FY25, with EBITDA margins rising to 24.6%. The company’s total assets as of March 31, 2025, stood at ₹3,310.71 crore, reflecting a 7.03% growth from the previous year. This robust financial performance, coupled with the positive regulatory outcome, underscores the company’s strong operational capabilities and strategic positioning in the pharmaceutical sector.

What’s Next?

The USFDA’s EIR with a VAI classification for Unit VI is a positive regulatory signal, allowing Shilpa Medicare to continue exports without disruption. The company is expected to address observations voluntarily, reducing compliance risks. With strong FY25 earnings growth and a 30% jump in EBITDA, investor sentiment remains upbeat. The facility’s approvals from global regulators and filings for transdermal products in Europe point to expansion opportunities. If execution stays on track, the stock may test its 52-week high of ₹1,000 in the near term.

About the Company

Shilpa Medicare Ltd, listed on both BSE and NSE since December 2009, operates in the pharmaceutical sector, with a focus on complex generics and speciality products. The company is part of the Nifty Total Market index and has a high valuation with an adjusted P/E of 103.14.

REF: https://nsearchives.nseindia.com/corporate/SHILPAMED_16072025100947_SE_USFDA_EIR_Unit_VI.pdf

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations